Valantine Hannah 4

4 · BridgeBio Pharma, Inc. · Filed Mar 3, 2026

Form 4

Period: 2026-02-27

Director

Transactions

Exercise/Conversion
Common Stock
2026-02-27$48.45/sh+25,484$1,234,700→ 32,949 total
Sale
Common Stock
[F1][F2]
2026-02-27$67.08/sh−14,584$978,285→ 18,365 total
Sale
Common Stock
[F1][F3]
2026-02-27$67.84/sh−10,900$739,496→ 7,465 total
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-02-27−25,484→ 0 total
Exercise: $48.45Exp: 2031-10-24→ Common Stock (25,484 underlying)

Holdings

Footnotes (4)

[F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
[F2]Represents the weighted average sale price of the shares sold from $66.42 to $67.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
[F3]Represents the weighted average sale price of the shares sold from $67.42 to $68.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
[F4]The stock option vests and becomes exercisable in three annual installments after October 25, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

Signature

/s/ Will Solis, Attorney-in-Fact|2026-03-03

Documents

1 file